Livermore, United States
S2 Genomics, founded in 2016, is a pioneering company in the fields of Biotechnology and Health Care. With its headquarters in the United States, the company is at the forefront of innovation by providing solutions that automate the conversion of raw tissues into single cells or nuclei, crucial for genomics and cell biology studies.
The company's slogan, "Reimagine your single-cell research with automation," aptly encapsulates its mission to streamline the research process in these scientific fields. By reducing the manual workload, S2 Genomics significantly enhances research efficiency and accuracy.
In a significant milestone, the company secured a $16.00M Series A investment on January 23, 2024. This round was led by prominent investors such as BroadOak Capital Partners, HealthTech Capital, and RCT. This financial backing will likely propel S2 Genomics towards further technological advancements and market penetration, making it an attractive prospect for investors seeking opportunities in the biotechnology sector.
